MDXHB Stock Overview
A commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
MDxHealth SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.84 |
| 52 Week High | €4.08 |
| 52 Week Low | €2.84 |
| Beta | 0.79 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -69.36% |
| 5 Year Change | -82.16% |
| Change since IPO | -88.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| MDXHB | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | 1.7% |
| 1Y | n/a | -16.3% | 8.4% |
Return vs Industry: Insufficient data to determine how MDXHB performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how MDXHB performed against the UK Market.
Price Volatility
| MDXHB volatility | |
|---|---|
| MDXHB Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: MDXHB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MDXHB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 255 | Mike McGarrity | mdxhealth.com |
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010.
MDxHealth SA Fundamentals Summary
| MDXHB fundamental statistics | |
|---|---|
| Market cap | €82.41m |
| Earnings (TTM) | -€41.11m |
| Revenue (TTM) | €58.42m |
1.4x
P/S Ratio-2.0x
P/E RatioIs MDXHB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDXHB income statement (TTM) | |
|---|---|
| Revenue | US$63.69m |
| Cost of Revenue | US$25.20m |
| Gross Profit | US$38.48m |
| Other Expenses | US$83.30m |
| Earnings | -US$44.82m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.64 |
| Gross Margin | 60.42% |
| Net Profit Margin | -70.37% |
| Debt/Equity Ratio | 201.8% |
How did MDXHB perform over the long term?
See historical performance and comparison